Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study have?
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study has 338 citations in the OpenAlex counts ScholarIQ stores.
When was Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study published?
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study has 2021 year in the ScholarIQ index.
What is the open-access status of Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study?
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study has bronze oa status in the ScholarIQ index.
What is the DOI of Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study?
The DOI for Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study is on the source record.
What is the PMID of Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study?
The PMID for Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study is on the source record.
What is the OpenAlex record for Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study?
The OpenAlex for Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study is on the source record.